Association of Helicobacter pylori with Parkinson's Disease.
10.3988/jcn.2017.13.2.181
- Author:
Kandadai Rukmini MRIDULA
1
;
Rupam BORGOHAIN
;
Vupparalli CHANDRASEKHAR REDDY
;
Venkata Chandrasekhar Srinivasarao BANDARU
;
Turaga SURYAPRABHA
Author Information
1. Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, India. rukminimridula@gmail.com
- Publication Type:Original Article
- Keywords:
Parkinson's disease;
H. pylori infection;
prevalence;
triple therapy;
Indian patients
- MeSH:
Follow-Up Studies;
Helicobacter pylori*;
Helicobacter*;
Humans;
Levodopa;
Male;
Nervous System Diseases;
Outcome Assessment (Health Care);
Parkinson Disease*;
Prevalence;
Prospective Studies
- From:Journal of Clinical Neurology
2017;13(2):181-186
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND PURPOSE: Parkinson's disease (PD) is a major neurological disorder that requires lifelong treatment, and the combined presence of Helicobacter pylori (H. pylori) infection can increase the required anti-PD medications. We aim to investigate the effect of H. pylori infection in Indian PD patients. METHODS: We prospectively recruited 36 PD patients from December 2007 to January 2011. All patients underwent a detailed neurological evaluation and serological examination for H. pylori infection. Seropositive and seronegative patients were considered to be the cases and controls, respectively. All patients who were seropositive received triple therapy for 2 weeks. Outcome measures of the mean ‘off’ Unified Parkinson's Disease Rating Scale (UPDRS)-III score, mean ‘on’ UPDRS-III score, mean onset time, mean ‘on’ duration, and mean daily ‘on’ time were measured at baseline and at a 3-week follow-up. RESULTS: H. pylori-IgG positivity was present in 18 (50%) PD patients. The prevalence of men (72.2% vs. 33.3%), mean duration of disease (13.8 vs. 12.5) and mean levodopa equivalent daily dose (824 mg vs. 707 mg) were significantly higher among H. pylori positive patients than in controls (p<0.0001). Controls had a significantly longer ‘on’ duration and daily ‘on’ time, and better ‘on’ UPDRS-III scores. Seropositive patients took a significantly longer time to turn ‘on’ after a levodopa challenge. At the 3-week follow-up, H. pylori eradication significantly improved the mean ‘on’ UPDRS-III score, onset time, ‘on’ duration, and daily ‘on’ time. CONCLUSIONS: H. pylori infection was present in 50% of Indian PD patients. H. pylori seropositivity was associated with a poor response to levodopa and increased medication usage, while eradication therapy was associated with better patient outcomes.
